A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
3 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 3
- Patients
- 315 (final count)
- Started
- Sep 9, 2024
- Main results expected
- Jan 10, 2028
- Fully finished
- Apr 24, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Area under the serum concentration-time curve (AUC) from time 0 to 21 days (AUC21d) of ABP 234
Measured over: 21 days
AUC21d of pembrolizumab (US)
Measured over: 21 days
AUC21d of pembrolizumab (EU)
Measured over: 21 days
AUC at steady state between Week 16 and Week 19 (AUCtau_ss) of ABP 234
Measured over: Week 16 through Week 19
AUCtau_ss of pembrolizumab (US)
Measured over: Week 16 through Week 19
AUCtau_ss of pembrolizumab (EU)
Measured over: Week 16 through Week 19
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06311721 · record last updated 2026-05-06 · checked 2026-11-09 15:47 UTC